Selank Research for Anxiety
An evidence-based overview of research examining Selank in the context of anxiety. This page synthesizes findings from peer-reviewed literature.
Research Summary
Selank is approved in Russia for anxiety disorders and neurasthenia. Clinical trials demonstrate anxiolytic efficacy comparable to benzodiazepines without the sedation, cognitive impairment, or dependence potential. The mechanism involves GABA-A receptor allosteric modulation, similar to benzodiazepines but with a different binding profile. Studies show reduced anxiety scores on validated assessment tools. Selank is not approved in Western countries. Russian clinical trials provide the evidence base, but independent Western replication is limited.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Anxiety
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Selank may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.